ADMA

ADMA Biologics, Inc. (ADMA) Analyst Note

Date: 2026-06-13 Current Price: $8.31

1. Structural Readiness

• Conservative Entry: Not yet actionable (requires confirmed close above resistance).
• Aggressive/Pre-Breakout Entry: $8.31 (Current Price).
• Breakout Level: Not yet established (requires price action above the recent consolidation high).
• Current Price: $8.31.
• Extension: Not applicable (price is within the consolidation range, not extended above a breakout).
• ATR Context: Current ATR is 4.6% (High). This indicates elevated volatility, which is consistent with a "forming" coil in a biotech sector where earnings catalysts drive wide swings. The 4.6% ATR sits within the historical "sweet spot" (4–6%) for structural quality, suggesting the setup has sufficient momentum to move but is not yet in the "extreme" danger zone (>8%).
• Pivot Strength: Not yet confirmed (requires breakout).

2. Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Immunology & Inflammation.
• Directness: Tier Direct. ADMA is a primary beneficiary of the secular demand for immunoglobulin therapies. The company is not a peripheral player; it is a manufacturer and marketer of specialty biologics (ASCENIV, BIVIGAM) directly addressing the "dislocated state" of the plasma fractionation industry where demand outpaces supply.
• Thesis Weighting: The exposure is highly concentrated in the Immunology & Inflammation sector. There are no secondary secular themes listed in the membership data; the conviction rests entirely on the supply/demand dislocation in the plasma-derived IG market and the company's ability to leverage its manufacturing capacity to capture this demand. The "Margin Inflector" archetype suggests the thesis is not just top-line growth, but a structural improvement in profitability driven by yield enhancements.

3. Business Overview

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients.

• Core Products:
• ASCENIV: An IVIG product indicated for Primary Humoral Immunodeficiency (PI). As of the May 2026 earnings call, ASCENIV revenue was $97.5 million, representing 28% year-over-year growth.
• BIVIGAM: Another IVIG product.
• Nabi-HB: Used for Hepatitis B exposure.
• Manufacturing & Supply Chain:
• ADMA operates its own source plasma collection facilities.
• Supply Agreements: ADMA has secured critical plasma supply through agreements with Grifols and KEDPlasma, each providing a minimum of 35,000 liters of RSV plasma annually.
• Yield Enhancement: In April 2025, the FDA approved a "Yield Enhancement" process for ASCENIV and BIVIGAM. Management states this process increases production yields by 20% or more from the same starting plasma volume. Fiscal year 2026 is the first full year of yield-enhanced production.
• Regulatory Milestones:
• Pediatric Expansion: In May 2026, the FDA approved the expansion of ASCENIV's label to include pediatric patients two years of age and older.
• Pipeline: The company is on track to submit a pre-IND package for SG-001 (a potential $300M–$500M peak opportunity) later in 2026.
• Financial Guidance (as of May 2026 Earnings):
• Full Year 2026 Revenue: $530 million to $560 million.
• Full Year 2026 Adjusted EBITDA: $265 million to $300 million.
• Full Year 2026 Adjusted Net Income: $170 million to $200 million.
• Capacity Outlook: Management projects the facility could support annual revenues greater than $635 million in 2026 and $775 million in 2027 based on current yields and capacity expansions.

4. Archetype and Conviction

• Archetype: Margin Inflector.
• Fit: The company is transitioning from a pure growth story to a margin-expansion story. The "Yield Enhancement" process (approved April 2025) is the primary driver. By increasing yields by 20%+ without a proportional increase in plasma costs (fixed supply agreements), the company is structurally improving its cost of goods sold (COGS). This is explicitly framed by management as the driver for "sustained margin expansion" in FY2026.
• Valuation Context:
• Forward consensus EPS for FY1 is $0.8275 and FY2 is $1.0149.
• At a price of $8.31, the stock trades at approximately 10x FY1 EPS and 8.2x FY2 EPS.
• Given the guidance of $170M–$200M net income and a market cap implied by the share count (not explicitly provided, but derived from EPS/Price), the valuation appears to be pricing in a "mid-cap" biotech with significant margin leverage, rather than a high-growth speculative biotech.
• Conviction Stack:
• Thesis Strength: High. The secular demand for IG products is a structural issue (supply < demand) that ADMA is uniquely positioned to solve via its yield tech.
• Evidence Quality: High. The evidence is recent (May 2026), specific (revenue figures, yield percentages, FDA approvals), and consistent across earnings transcripts and SEC filings.
• Structural Quality: The 4.6% ATR suggests a healthy, active market with enough volatility to support a breakout, but not so much as to indicate panic.
• Rerating Potential: Significant. The market is currently pricing in the FY2026 guidance, but the "Margin Inflector" narrative (20% yield lift) suggests the market may not have fully priced in the *sustainability* of these margins or the potential for the $775M revenue run-rate in 2027.

5. Invalidation, Strengthening, and Gaps

• Gaps in Evidence:
• Share Count: The exact number of shares outstanding is not provided in the evidence block, making precise market cap and fully diluted EPS calculations impossible to verify independently from the provided consensus EPS.
• SG-001 Timeline Specifics: While the pre-IND submission is expected "later this year," the specific date or potential for clinical trial delays is not detailed.
• Plasma Price Escalation: The agreements with Grifols and KEDPlasma include "escalating price per liter." The specific rate of escalation for 2026 is not quantified in the provided text, which could impact the margin inflector thesis if plasma costs rise faster than yield improvements.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: High Key evidence: 1) FDA approval of ASCENIV pediatric label expansion in May 2026 driving top-line growth; 2) Yield Enhancement process approved April 2025 delivering 20%+ production lift, structurally inflecting margins in FY2026; 3) Strong revenue guidance ($530M-$560M) and EBITDA guidance ($265M-$300M) confirming secular demand for IG products. Expected path: Management expects sustained margin expansion as FY2026 becomes the first full year of yield-enhanced production. Revenue growth should continue to outpace cost increases, leading to a re-rating of the stock as the market recognizes the durability of the new margin profile. Expected horizon: 6 to 12 months for the thesis to fully play out as the yield benefits flow through the P&L and the SG-001 pipeline progresses. Failure mode to watch: A sustained drop in ASCENIV sales growth below the 28% YoY trajectory or a failure to secure the minimum plasma volumes required to maintain the yield advantage.